In the field of rare hematological diseases, every new scientific finding represents a step forward toward more effective and personalized treatments. Today, we are pleased to share the editorial published in The Lancet Haematology by Dr. Khaled Musallam, which analyzes the long-term data from the BELIEVE trial on the use of luspatercept in transfusion-dependent beta-thalassemia.
This new analysis, based on the extension phase of the study, has addressed many previously unanswered questions, providing a clearer overview of the role of luspatercept in treating this condition.
📄 Read the editorial: The Lancet Haematology
📑 Access the original article: The Lancet Haematology
These findings represent a significant contribution to the management of transfusion-dependent beta-thalassemia, opening new perspectives for patients and the scientific community.
Stay tuned for updates on the latest advancements in hematological research.
